Genaconazole

Genaconazole

SCHEMBL8937940

C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 17/20 0.67
CYP2C9 P11712 10/20 0.67
CYP2C19 P33261 10/20 0.67
LMNA P02545 2/20 0.67
CYP2B6 P20813 1/20 0.67
CYP3A5 P20815 1/20 0.67
CYP3A7 P24462 1/20 0.67
MAPK1 P28482 1/20 0.67
CYP3A43 Q9HB55 1/20 0.67
CYP46A1 Q9Y6A2 1/20 0.67
HSP90AA1 P07900 1/20 0.62
CYP19A1 P11511 1/20 0.62
CYP11B1 P15538 1/20 0.62
CYP11B2 P19099 1/20 0.62
ADRA1A P35348 1/20 0.62
CYP51A1 Q16850 1/20 0.62
CYP1A2 P05177 6/20 0.61
CYP2D6 P10635 6/20 0.61
KCNH2 Q12809 3/20 0.57
ABCG2 Q9UNQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Genaconazole SCHEMBL9774648 1.00 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19LMNACYP2B6
Genaconazole SCHEMBL30011920 1.00 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19LMNACYP2B6
Genaconazole SCHEMBL1455652 1.00 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19LMNACYP2B6
Genaconazole SCHEMBL8937907 1.00 CYP3A4 (0.67) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL31512306 0.91 CYP3A4 (0.56) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL9119825 0.90 CYP3A4 (0.66) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL9044739 0.89 CYP3A4 (0.64) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL9044551 0.89 CYP3A4 (0.64) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL9044565 0.89 CYP3A4 (0.64) CYP3A4CYP2C9CYP2C19LMNACYP2B6
SCHEMBL9118073 0.89 CYP3A4 (0.63) CYP3A4CYP2C9CYP2C19LMNACYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637708-A2 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE Novaliq GmbH (DE) 2025-10-29 EP claimed
WO-2024133913-A9 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE NOVALIQ GMBH (DE) 2025-03-20 WO claimed
WO-2024133913-A2 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE NOVALIQ GMBH (DE) 2024-06-27 WO claimed
US-4988722-A Fungicide solutions for injections SCHERING CORPORATION (US) 1991-01-29 US claimed
EP-2841109-B1 PRODRUGS OF HYDROXYL-COMPRISING DRUGS ASCENDIS PHARMA AS (DK) 2026-04-15 EP disclosed
EP-4637708-A2 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE Novaliq GmbH (DE) 2025-10-29 EP disclosed
US-12370352-B2 Nasal and ophthalmic delivery of aqueous corticosteroid solutions CYDEX PHARMACEUTICALS, INC. (US) 2025-07-29 US disclosed
CN-119980482-A Method for preparing On-DNA sulfinic acid structural compound and application thereof 康龙化成(宁波)科技发展有限公司 2025-05-13 CN disclosed
WO-2024133913-A9 SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE NOVALIQ GMBH (DE) 2025-03-20 WO disclosed
US-20250032457-A1 METHODS OF TREATING ANDROGENIC ALOPECIA AND/OR SKIN CONDITIONS RAUCH ERIC (US) 2025-01-30 US disclosed
CN-118257005-B On-DNA beta-hydroxy sulfone structural compound, synthetic method and application thereof 康龙化成(宁波)科技发展有限公司 2024-11-12 CN disclosed
CN-118257005-A On-DNA beta-hydroxy sulfone structural compound, synthetic method and application thereof 康龙化成(宁波)科技发展有限公司 2024-06-28 CN disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 US disclosed
US-20220339414-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2022-10-27 US disclosed
CN-114787200-A Method for forming inclusion complex using hydrophilic beta-cyclodextrin derivatives and compositions thereof 塔卡美国公司 2022-07-22 CN disclosed
EP-4011396-A1 RELEASABLE CONJUGATES QuiaPEG Pharmaceuticals AB (SE) 2022-06-15 EP disclosed
WO-2022060744-A1 METHODS OF TREATING ANDROGENIC ALOPECIA AND/OR SKIN CONDITIONS RAUCH ERIC (US) 2022-03-24 WO disclosed
US-5545558-A SELECTIVE HYDROLYSIS OF THE COORESPONDING OXYKETONE SCHERING CORPORATION (US) 1996-08-13 US disclosed
EP-0537921-A2 Enzymatic synthesis of chiral alpha-hydroxyketones and derivatives SCHERING CORPORATION (US) 1993-04-21 EP disclosed
WO-1993007289-A1 ENZYMATIC SYNTHESIS OF CHIRAL α-HYDROXYKETONES AND DERIVATIVES SCHERING CORPORATION (US) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370352-B2 Nasal and ophthalmic delivery of aqueous corticosteroid solutions CRH, HRH1, IL5 CYP3A4 2163/4885CYP2C9 2205/4885CYP2C19 1048/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 CYP3A4 209/4885CYP2C9 131/4885CYP2C19 120/4885
US-20220339414-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CRH, HRH1, IL5 CYP3A4 2163/4885CYP2C9 2205/4885CYP2C19 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.